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Background: IL-6 is a proinflammatory cytokine reported to play an important role in the induction of cerebral
vasospasm after subarachnoid hemorrhage (SAH). Suppressor of cytokine signaling 3 (SOCS3) is known to act as an
inhibitor of signal transduction of IL-6. However, there have been no reports on the expression of SOCS3 in cerebrospinal
fluid (CSF) after SAH.
Findings: The concentration of IL-6 was measured serially up until day 10, in CSF of eight patients with SAH. CSF samples
obtained from patients suffering from an unruptured aneurysm were used as controls. The expression of SOCS3 in CSF was
further examined by immunoprecipitation methods. Concentrations of IL-6 in CSF increased immediately after the onset of
SAH and remained chronically elevated over control values. SOCS3 was significantly expressed in CSF on days 1 to 3 after
SAH.
Conclusions: Our findings suggest that SOCS3 regulates IL-6 signaling as an antagonist in CSF, immediately following SAH.
As the expression of SOCS3 decreases after day 5, IL-6 signals might then be more easily transmitted, presumably resulting
in cerebral vasospasm.
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Introduction
Intracisternal injection of beads alone without hemorrhage
in the subarachnoid space induces persistent and severe
cerebral vasospasm [1], which suggests that inflammation
plays an important role in the induction of cerebral vaso-
spasm. Mathiesen et al. [2] first described increased IL-6
levels in cerebrospinal fluid (CSF) after subarachnoid
hemorrhage (SAH), suggesting that the severe inflamma-
tory response affects the central nervous system. In the
case of severe meningitis and head trauma, severe cerebral
vasospasm may be lethal. In such cases, massive produc-
tion of IL-6 in CSF has been reported [3,4].
IL-6 is known to induce activation of the janus kinase/
signal transducer and activator of transcription (JAK/
STAT) signaling pathway and transduce signals from the
cell surface into the nucleus, resulting in the transcription* Correspondence: kosuka@aichi-med-u.ac.jp
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unless otherwise stated.of immediate early genes [5]. The transcription of the sup-
pressor of cytokine signaling 3 (SOCS3) gene increases rap-
idly in response to activation of IL-6, and SOCS3 acts as an
inhibitor of signal transduction of IL-6 [6]. Whether the in-
crease of IL-6 concentration in CSF after SAH is accom-
panied by an augmentation of SOCS3 remains unknown.
The present study was therefore undertaken to clarify
the time-course of expression of SOCS3 in CSF after
SAH. Our study demonstrates that SOCS3 is signifi-
cantly expressed in CSF on days 1 to 3 after onset of
SAH.
Methods
Patients and control subjects
Eight patients who underwent surgical obliteration of
cerebral aneurysms at Aichi Medical University Hospital
within one day after onset of SAH were enrolled in this
study. The patients ranged in age from 41 to 66 years
(mean 53 years); 3 were men and 5 were women. Initial
clinical status was classified according to Hunt and
Kosnik grade; four patients were grade II and four weretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Osuka et al. Journal of Neuroinflammation 2014, 11:142 Page 2 of 4
http://www.jneuroinflammation.com/content/11/1/142grade III. The amount of blood in the subarachnoid
space was defined by Fisher’s criteria; six patients were
group 3 and two were group 4. Locations of all aneu-
rysms were in the anterior circulation. After aneurysms
were clipped, a cisternal catheter was inserted into the
chiasmatic or prepontine cistern and postoperative CSF
samples were collected serially with a drainage tube over
the following ten days. Cerebral angiography or mag-
netic resonance angiography revealed focal cerebral
vasospasm in some cases. No patients suffered from
clinically symptomatic vasospasm or developed infec-
tion. Clinical outcomes were assed using the Glasgow
Outcome Scale; six patients were classified as good re-
covery and two classified as moderate disability due to
initial brain damages. As a control, CSF samples were
obtained from six patients (mean 59 years) undergoing
neck clipping for unruptured cerebral aneurysm. All
samples were immediately centrifuged and supernatant
fluids were stored at −80°C until analysis. The Ethics
Committee of Aichi Medical University approved this
clinical experiment.Analysis of IL-6 in CSF
IL-6 was measured using an enzyme immuno-assay
(EIA; Catalogue Number D6050, R&D Systems, Inc.,
Minneapolis, MN, USA). The limit of detection of this









Figure 1 Serial changes of IL-6 in cerebrospinal fluid (CSF) from
eight patients with subarachnoid hemorrhage. IL-6 was measured
using an enzyme immuno-assay kit. Data are represented as
box-and-whisker plots indicating the median, the upper and
lower quartile, the largest and the lowest value. CNT, control
CSF from six patients with unruptured cerebral aneurysmDetection of SOCS3 in CSF
CSF samples after SAH in five patients were used for
further study. CSF (500 μl) and SOCS3 polyclonal anti-
bodies (2 μl; Catalogue Number sc-9023, Santa Cruz Bio-
technology, Dallas, TX, USA) were incubated with gentle
shaking for 1 hour at 4°C. After this procedure, protein G
Sepharose (20 μl, GE Healthcare, Buckinghamshire, UK)
was added and incubated overnight at 4°C. The immu-
nocomplexes were then washed with PBS and boiled in
50 μl of Laemmli sample buffer for 10 minutes.
All sample buffers were centrifuged and supernatant
samples were subjected to 10 % sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Proteins
were then transferred to polyvinylidene difluoride
(PVDF) membranes under wet conditions and incu-
bated with primary monoclonal antibodies against
SOCS3 (Catalogue Number 10141, Immuno-Biological
Laboratories, IBL, Gunma, Japan) at a dilution of
1:1,000 overnight at 4°C. After washing, the mem-
branes were incubated with secondary antibodies con-
jugated to horseradish peroxidase (SIGMA, Saint
Louis, MO, USA) at a dilution of 1:3,000 for 30 minutes
at room temperature. Reactions were developed with
electrochemiluminescence (ECL) (GE Healthcare).
Bands were scanned with image analyzer LAS-1000(GE Healthcare) and intensities were quantitated using
the NIH IMAGE program.
Statistical analysis
Data are represented as box-and-whisker plots indicating
the median, the upper and lower quartile, the largest
and the lowest value in the data set. Data are expressed
as the mean ± SD values. Significant differences between
the groups were assessed by one-way analysis of variance
(ANOVA) followed by the Bonferroni/Dunn for multiple
comparisons. Statistical significance was concluded at
the P < 0.05 level.
Results
Change in IL-6 after SAH
CSF concentrations of IL-6 were remarkably high in the
acute stage (29,869.6 ± 26,715.3 pg/ml on day 1) - more
than one thousand times the control CSF value (11.4 ±
0.9 pg/ml) -and remained chronically elevated (Figure 1).
Expression of SOCS3 after SAH
SOCS3 has been previously identified as an inhibitor of
the JAK/STAT signaling pathway activated by IL-6. We
examined the expression of SOCS3 in the CSF by immu-
noprecipitation methods. As shown in Figure 2, SOCS3
was significantly expressed on days 1 to 3 after onset of
SAH compared with controls and days 5 to 7 post-SAH.
Discussion
In this study we demonstrated that concentrations of
IL-6 in CSF increase immediately after the onset of
SAH and are maintained for a week after the event. In
addition, a significant increase in SOCS3 in CSF was
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Figure 2 Expression of suppressor of cytokine signaling 3
(SOCS3) in cerebrospinal fluid (CSF) from five patients. SOCS3
was immunoprecipitated from CSF with polyclonal anti-SOCS3
antibodies, and the resulting immunocomplexes were subjected
to immunoblot analysis using monoclonal anti-SOCS3 antibodies.
Data show the amount of SOCS3 after subarachnoid hemorrhage
(SAH) relative to that of the control, using the values of the median,
the upper and lower quartile with maximum/minimum whiskers.
Representative western blot analysis from one individual is shown
(days 1 to 10). CNT, control CSF from unruptured cerebral
aneurysm; *P < 0.05 denotes a significant difference between the
control and SAH groups, determined by analysis of variance
followed by the Bonferroni/Dunn for multiple comparisons.
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have been previously reported [2,7-9], which is consist-
ent with our data. Recently, Schoch et al. argued that
IL-6 is a reliable early marker for predicting vasospasm
on days 4 and 5 before clinical onset [9]. Intracisternal
injection of IL-6 itself induces long-lasting vasoconstric-
tion in canines [8]. Moreover, IL-6 is known to induce
phosphorylation of JAK1 and STAT3 in the rat basilar
artery after SAH and transduces signals into the nucleus
[10], resulting in the transcription of immediate early
genes. Considering these data, IL-6 might play an im-
portant role in inducing cerebral vasospasm through the
regulation of this JAK/STAT signaling pathway.
The SOCS protein is one of the key factors involved in
the negative regulation of JAK/STAT signaling [6]. SOCS
genes are transcriptionally activated in response to
STAT-mediated mechanisms. SOCS proteins interact
with the catalytic domains of JAK proteins and inhibit
JAK kinase activity, resulting in the inhibition of STAT
activation [11]. This negative feedback pathway tightly
regulates cytokine-induced activation of STATs. IL-6
promotes acute and chronic inflammatory disease in
SOCS3 knock-out mice in vivo [12]. In response to vas-
cular injury, the JAK/STAT signaling pathway is involved
with neointimal formation and atherosclerotic plaque
progression [13,14]. Taken all together, SOCS3 might
regulate the JAK/STAT signaling pathway activated by
IL-6, and subsequent transcription of genes in the basilar
artery immediately after SAH. Although no apparent re-
lationship between outcome, IL-6 levels and SOCS3 wasobtained from this limited study [see Additional file 1:
Figure S1], we speculate that the expression of SOCS3
decreases after day 5 and IL-6 signals might then be
more easily transmitted, presumably resulting in cerebral
vasospasm. Cerebral vasospasm is a relevant problem
that affects outcome [15,16]. The use of SOCS3 could be
one of the modalities to reduce cerebral vasospasm in
the future.
Conclusion
The present investigation has, for the first time, clarified
chronological expressions of SOCS3 in CSF after SAH.
Of particular note is our finding that SOCS3 is signifi-
cantly expressed in CSF on days 1 to 3 after onset of
SAH, suggesting that SOCS3 may inhibit IL-6 signal
transduction immediately after SAH. Further studies
using SOCS3 as an antagonist of IL-6 should be con-
ducted to more precisely clarify the mechanisms of IL-6
regulation after SAH.
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Additional file
Additional file 1: Figure S1. Relationship of IL-6 and suppressor of
cytokine signaling 3 (SOCS3) in cerebrospinal fluid (CSF) from five patients.
We measured the concentrations of IL-6 within CSF on day 1 from five more
patients. Three CSF samples contained IL-6 less than 10,000 pg/ml (low
group) and 2 CSF samples contained IL-6 more than 20,000 pg/ml (high
group). SOCS3 was immunoprecipitated with polyclonal anti-SOCS3
antibodies from these five CSFs, and the resulting immunocomplexes
were subjected to immunoblot analysis using monoclonal anti-SOCS3
antibodies. Western blot analysis revealed that band intensity of
SOCS3 was detected more clearly from the high group than the low
group, suggesting that there might be a tight relationship between IL-6
and SOCS3.
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